arrow_back Back to App

Expanding In-Home IVIG Coverage for Seniors Under Medicare

This bill aims to expand access to in-home intravenous immune globulin (IVIG) administration for seniors covered by Medicare. Starting January 1, 2027, Medicare will cover in-home IVIG for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, in addition to primary immune deficiency diseases. This means more individuals will be able to receive necessary treatment in the comfort of their own homes, potentially improving their quality of life and reducing the burden of medical facility visits.
Key points
Effective January 1, 2027, Medicare will cover in-home IVIG administration for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
Previously, in-home IVIG coverage was primarily for primary immune deficiency diseases.
Payment rates for IVIG administration may vary based on the treated condition, ensuring fair cost coverage.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_1143
Sponsor: Rep. Smith, Adrian [R-NE-3]
Process start date: 2025-02-07
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Medicare IVIG Access Enhancement Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_1143.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-02-07.

What are the main provisions?

Key points include:

  • Effective January 1, 2027, Medicare will cover in-home IVIG administration for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
  • Previously, in-home IVIG coverage was primarily for primary immune deficiency diseases.
  • Payment rates for IVIG administration may vary based on the treated condition, ensuring fair cost coverage.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Smith, Adrian [R-NE-3].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Benefits